PTTG1 Reprograms Asparagine Metabolism to Promote Hepatocellular Carcinoma Progression

Cancer Res. 2023 Jul 14;83(14):2372-2386. doi: 10.1158/0008-5472.CAN-22-3561.

Abstract

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and has a poor prognosis. Pituitary tumor transforming gene 1 (PTTG1) is highly expressed in HCC, suggesting it could play an important role in hepatocellular carcinogenesis. Here, we evaluated the impact of PTTG1 deficiency on HCC development using a diethylnitrosamine (DEN)-induced HCC mouse model and a hepatitis B virus (HBV) regulatory X protein (HBx)-induced spontaneous HCC mouse model. PTTG1 deficiency significantly suppressed DEN- and HBx-induced hepatocellular carcinogenesis. Mechanistically, PTTG1 promoted asparagine synthetase (ASNS) transcription by binding to its promoter, and asparagine (Asn) levels were correspondingly increased. The elevated levels of Asn subsequently activated the mTOR pathway to facilitate HCC progression. In addition, asparaginase treatment reversed the proliferation induced by PTTG1 overexpression. Furthermore, HBx promoted ASNS and Asn metabolism by upregulating PTTG1 expression. Overall, PTTG1 is involved in the reprogramming of Asn metabolism to promote HCC progression and may serve as a therapeutic and diagnostic target for HCC.

Significance: PTTG1 is upregulated in hepatocellular carcinoma and increases asparagine production to stimulate mTOR activity and promote tumor progression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Asparagine / genetics
  • Asparagine / metabolism
  • Carcinoma, Hepatocellular* / pathology
  • Gene Expression Regulation, Neoplastic
  • Hepatitis B virus / metabolism
  • Liver Neoplasms* / pathology
  • Mice
  • Prognosis
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Asparagine
  • TOR Serine-Threonine Kinases
  • PTTG1 protein, mouse